Researchers have recently cautioned horse owners currently treating horses diagnosed with pituitary pars intermedia dysfunction (PPID, or equine Cushing's syndrome) that the compounded form of the drug pergolide mesylate can become unstable and potentially ineffective.
"Since the United States Food and Drug Administration (FDA) recommended the It's FREE and you'll get full access to more than 20,000 articles, video, free reports & more.
To continue reading this article, become a member of TheHorse.com.
